2018 Career Support Funds Granted
In 2018, we funded $8.5 million across 19 fellowships,supporting emerging and established cancer researchers in NSW.
2018 Career Development Fellowships
Career Development Fellowships are for mid-career researchers who demonstrate the potential to undertake research that will have major significance to cancer outcomes.
| Administering Institution | Grantee | Grant Title | Funding (excl. GST) | |
|---|---|---|---|---|
|
Garvan Institute of Medical Research |
Dr Mandy Ballinger |
A Clinical Genomics Program focused on Early Onset Cancers |
$600,000 |
|
|
Garvan Institute of Medical Research |
Dr Thomas Cox |
Transient tissue ‘priming’ as a therapeutic modality to impair pancreatic cancer progression and improve sensitivity to adjuvant therapies |
$341,667 |
|
|
The University of Sydney |
Dr Patric Jansson |
Development of Innovative Chemotherapeutics that Target P-Glycoprotein-Expressing Cancers to Overcome Drug Resistance |
$150,000 |
|
|
The University of Sydney |
Dr Zaklina Kovacevic |
Overcoming breast cancer heterogeneity and resistance using a novel therapeutic approach targeting the metastasis suppressor NDRG1 |
$75,000 |
|
|
The University of Sydney |
Associate Professor Ricky O'Brien |
The Clinical Translation of NSW Invented Tumour Motion Management Technologies in Cancer Radiotherapy |
$600,000 |
|
|
The University of Sydney |
Dr Justin Jong-Leong Wong |
Defining the role of aberrant splicing (intron retention) in the development and maintenance of acute myeloid leukaemia |
$150,000 |
|
|
$1,916,667 |
||||
2018 Early Career Fellowships
Early Career Fellowships are aimed at encouraging researchers to build on their research capability and become leaders of their own research team.
| Administering Institution | Grantee | Grant Title | Funding (excl. GST) | |
|---|---|---|---|---|
|
Garvan Institute of Medical Research |
Mr Ira Deveson |
Representing the cancer genome with synthetic DNA spike-in controls |
$448,200 |
|
|
Garvan Institute of Medical Research |
Dr David Herrmann |
Pinpointing the pro-invasive plasticity of breast cancer in vivo by targeting the Src/EMT signalling axis |
$600,000 |
|
|
Garvan Institute of Medical Research |
Mrs Heloisa Helena Milioli |
Expanding the repertoire of therapies targeting sex steroid receptors in breast cancer |
$600,000 |
|
|
Garvan Institute of Medical Research |
Dr Max Nobis |
Intravital imaging using AKT and DNA damage biosensor mice for drug target validation to improve PARP and PI3K inhibition in pancreatic cancer |
$600,000 |
|
|
Macquarie University |
Dr Andrew Care |
Biological nanoparticles for targeted and light-controllable anticancer drug delivery |
$367,010 |
|
|
The University of Sydney |
Dr Noa Lamm-Shalem |
Targeting novel pathways in the DNA replication-stress response to kill cancer |
$599,135 |
|
|
The University of Sydney |
Dr Alexander Sobinoff |
Targeting telomeric repeat-binding factor 2 (TRF2) with small molecule inhibitors to promote a DNA damage response and prevent cancer cell growth |
$568,816 |
|
|
The University of Sydney |
Dr Alexander Menzies |
Predictive biomarkers of response to immunotherapy in melanoma |
$90,000 |
|
|
The University of Sydney |
Dr Doan Trang Nguyen |
Widely accessible high precision radiotherapy with Multi-modal Adaptive Tumour Tracking (MATT) |
$393,606 |
|
|
The University of Sydney |
Dr Ulf Schmitz |
Cooperating microRNAs for cancer therapy - a systems medicine approach |
$600,000 |
|
|
University of Newcastle |
Dr Mengna Chi |
Novel therapeutic applications for low THC containing medicinal hemp |
$600,000 |
|
|
University of Newcastle |
Dr Heather Lee |
Single-cell analysis for improved epigenetic therapy in acute myeloid leukaemia |
$538,000 |
|
|
University of New South Wales |
Dr Frances Byrne |
Developing new drugs that selectively kill cancer cells by targeting the Warburg Effect |
$590,041 |
|
|
$6,594,808 |
||||